Scientific article
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5
ContributorsBlumenkranz, Mark S; Bressler, Neil M; Bressler, Susan B; Donati, Guy; Fish, Gary Edd; Haynes, Laurie A; Lewis, Hilel; Miller, Joan W; Monés, Jordi M; Potter, Michael J; Pournaras, Constantin; Reaves, Al; Rosenfeld, Philip J; Schachat, Andrew P; Schmidt-Erfurth, Ursula; Sickenburg, Michel; Singerman, Lawrence J; Slakter, Jason S; Strong, Andrew; Vannier, Stéphane
Published inArchives of ophthalmology, vol. 120, no. 10, p. 1307-1314
Publication date2002
Abstract
Keywords
- Aged
- Aged, 80 and over
- Choroid/blood supply
- Double-Blind Method
- Female
- Fovea Centralis
- Humans
- Macular Degeneration/complications/physiopathology
- Male
- Neovascularization, Pathologic/drug therapy/etiology
- Photochemotherapy
- Photosensitizing Agents/adverse effects/therapeutic use
- Porphyrins/adverse effects/therapeutic use
- Safety
- Visual Acuity
Affiliation entities Not a UNIGE publication
Citation (ISO format)
BLUMENKRANZ, Mark S et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. In: Archives of ophthalmology, 2002, vol. 120, n° 10, p. 1307–1314.
Main files (1)
Article (Published version)
Identifiers
- PID : unige:93210
- PMID : 12365909
ISSN of the journal0003-9950
